

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

### How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

### Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

### What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email [gram.formularyteam@nhs.scot](mailto:gram.formularyteam@nhs.scot).

Image courtesy of Baitong333 - image ID: 100128772/ [FreeDigitalPhotos.net](https://www.FreeDigitalPhotos.net)

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
abiraterone acetate 500mg, 1,000mg film-coated tablets	<a href="#">102</a>	[Off-label use] In combination with prednisolone and androgen deprivation therapy for the treatment of high-risk hormone-sensitive non-metastatic prostate cancer.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/01/2023
carfilzomib 10mg, 30mg, 60mg powder for solution for infusion (Kyprolis®)	<a href="#">104</a>	[Off-label use] Once-weekly regimen in combination with dexamethasone alone for the treatment of adults with multiple myeloma who have received at least one prior therapy.	Routinely available in line with national guidance, NCMAG 104 <a href="https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=0be71c76-711d-4dba-a057-f9758c25b5a7&amp;version=1">https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=0be71c76-711d-4dba-a057-f9758c25b5a7&amp;version=1</a>	17/01/2023
daratumumab 1,800mg solution for injection (Darzalex®)	<a href="#">2447</a>	In combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis.	Routinely available in line with national guidance, SMC 2447 <a href="https://www.scottishmedicines.org.uk/media/7045/daratumumab-darzalex-final-july-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/7045/daratumumab-darzalex-final-july-2022-for-website.pdf</a>	17/01/2023
Drovelis® 14.2mg/3mg film-coated tablets (estetrol/drospirenone)	<a href="#">2564</a>	Oral contraception.	Not routinely available as not recommended for use in NHS Scotland, SMC 2564 <a href="https://www.scottishmedicines.org.uk/media/7355/estetrol-drovelis-non-sub-final-dec-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/7355/estetrol-drovelis-non-sub-final-dec-2022-for-website.pdf</a>	17/01/2023
ferric maltol 30mg hard capsules (Feraccru®)	<a href="#">2500</a>	In adults for the treatment of iron deficiency.	Not routinely available as not recommended for use in NHS Scotland, SMC 2500 <a href="https://www.scottishmedicines.org.uk/media/7361/ferric-maltol-feraccru-resub-final-dec-2022-updated-12123-for-website.pdf">https://www.scottishmedicines.org.uk/media/7361/ferric-maltol-feraccru-resub-final-dec-2022-updated-12123-for-website.pdf</a>	17/01/2023
mobocertinib 40mg hard capsules (Exkivity®)	<a href="#">2516</a>	As monotherapy for the treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received prior platinum-based chemotherapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/01/2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
opicapone 50mg hard capsules (Ongentys®)	<a href="#">2430</a>	As adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCI) in adults with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations. <b>Restriction:</b> used after failure of entacapone, or in patients who cannot tolerate entacapone.	Routinely available in line with local guidance	17/01/2023
rasagiline 1mg tablets		For the treatment of idiopathic Parkinson's disease as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in adults with end of dose fluctuations.	Routinely available in line with local guidance	17/01/2023
setmelanotide 10mg/mL solution for injection (Imcivree®)	<a href="#">2565</a>	Treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.	Not routinely available as not recommended for use in NHS Scotland, SMC 2565 <a href="https://www.scottishmedicines.org.uk/media/7358/setmela-notide-imcivree-non-sub-final-dec-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/7358/setmela-notide-imcivree-non-sub-final-dec-2022-for-website.pdf</a>	17/01/2023
somatrogon 24mg, 60mg solution for injection in pre-filled pen (Ngenla®)	<a href="#">2493</a>	For the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.	Decision deferred to future meeting	17/01/2023
tepotinib 225mg film-coated tablets (Tepmetko®)	<a href="#">2535</a>	For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	17/01/2023
tisagenlecleucel 1.2 x 10 <sup>6</sup> – 6 x 10 <sup>8</sup> cells dispersion for infusion (Kymriah®)	<a href="#">2566</a>	Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.	Not routinely available as not recommended for use in NHS Scotland, 2566 <a href="https://www.scottishmedicines.org.uk/media/7360/tisagenlecleucel-kymriah-non-sub-final-dec-2022-for-website.pdf">https://www.scottishmedicines.org.uk/media/7360/tisagenlecleucel-kymriah-non-sub-final-dec-2022-for-website.pdf</a>	17/01/2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
trastuzumab 150mg, 420mg powder for concentrate for solution for infusion	<a href="#">105</a>	[Off-label use] Reduced treatment duration of 6-months in the neoadjuvant and adjuvant treatment pathways, for adults categorised as lower risk with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC).	Routinely available in line with national guidance, NCMAG 105 <a href="https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7bde2905-fff3-4b38-a218-9b6424458726&amp;version=-1">https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7bde2905-fff3-4b38-a218-9b6424458726&amp;version=-1</a>	17/01/2023
trastuzumab 600mg solution for subcutaneous injection (Herceptin®)	<a href="#">105</a>	[Off-label use] Reduced treatment duration of 6-months in the neoadjuvant and adjuvant treatment pathways, for adults categorised as lower risk with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC).	Routinely available in line with national guidance, NCMAG 105 <a href="https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7bde2905-fff3-4b38-a218-9b6424458726&amp;version=-1">https://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/ncmag_programme/idoc.ashx?docid=7bde2905-fff3-4b38-a218-9b6424458726&amp;version=-1</a>	17/01/2023